- Prof. Chris Holman, who has contributed to this blog in the past, recently started his own blog: Holman’s Biotech IP Blog. Formerly in-house counsel at a biotech company, Chris offers valuable insights on biotech IP law.
- “Big Pharma Faces Grim Prognosis” was the top story on the front page of the Wall Street Journal Thursday. It proclaims: “Over the next few years, the pharmaceutical business will hit a wall.” Summaries of the article appear on the WSJ Health Blog and Pharmalot.
- Watson Pharmaceuticals announced Thursday that it settled patent litigation with Novartis concerning its generic version of Novartis’s Exelon.
- Sun Pharma also announced a settlement with Novartis on Thursday, concerning its own generic version of Exelon. On October 23, Sun announced that the FDA granted final approval to its ANDA for generic Exelon.
- On Tuesday, Watson announced that it settled litigation with Biovail over its generic version of Cardizem LA. Biovail also put out its own press release.
- King Pharmaceuticals announced Monday that the Federal Circuit denied its petition for rehearing and rehearing en banc of the Federal Circuit’s September 11 decision invalidating the patent on Altace.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Orange Book Blog 
Leave a comment